Astrana Health Inc. ASTH 深 沪
已收盘 02-06 16:00:00 美东时间
21.10
-0.610
-2.81%
华盛通- 最 高22.14
- 今 开21.73
- 成交量 95.43万股
- 最 低 20.795
- 昨 收 21.71
- 总市值 10.58亿
- 52周最高 39.97
- 市盈率 静 23.46
- 换手率 1.90%
- 52周最低 20.12
- 委 比 87.33%
- 总股本 5015.56万
- 历史最高 123.51
- 量 比 1.62
- 振 幅 6.20%
- 历史最低 9.27
- 每 手 1
- 风险率 4.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 高露洁棕榄、再生元制药、伊士曼化工、威瑞森、Ameris、丘奇＆德怀特等获多家大行上调目标价
今日重点评级关注：Benchmark：维持Charter Communications"买入"评级，目标价从425美元升至455美元；BTIG：维持LifeStance Health Gr"买入"评级，目标价从10美元升至11美元
02-03 09:06
6 Analysts Assess Astrana Health: What You Need To Know
Astrana Health (NASDAQ:ASTH) has been analyzed by 6 analysts in the last three ...
02-02 20:00
Astrana Health Stock Slide Presents An Attractive Entry Point: Analyst
Astrana Health shares fell 22% after CMS proposed modest Medicare Advantage growth, but analyst says sell-off looks overdone and long-term benefits may emerge.
01-28 19:38
Astrana Health Inc. to Release Fourth Quarter and Year-End Financial Results
Astrana Health Inc. to Release Fourth Quarter and Year-End Financial Results Astrana Health, Inc. will release its fourth quarter and year-end 2025 financial results before the market opens on Monday, March 2, 2026. The company will host a conference call to discuss these results at 5:30 a.m. PT/8:3
01-26 21:01
美股大行评级 | 博通、Lululemon获10逾家大行上调目标价；好市多、RH遭大行下调目标价
今日重点评级关注：杰富瑞：维持ImmunityBio Inc Ordinary Shares"买入"评级，目标价从8美元升至9美元；B. Riley证券：维持WAVE Life Sciences"买入"评级，目标价从19美元升至37美元
2025-12-15 15:30
Needham Initiates Coverage On Astrana Health with Buy Rating, Announces Price Target of $28
Needham analyst Matthew Shea initiates coverage on Astrana Health (NASDAQ:ASTH) with a Buy rating and announces Price Target of $28.
2025-12-12 19:33
美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
2025-11-26 10:07
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
2025-11-25 10:27
Barclays Maintains Equal-Weight on Astrana Health, Lowers Price Target to $26
Barclays analyst Andrew Mok maintains Astrana Health (NASDAQ:ASTH) with a Equal-Weight and lowers the price target from $36 to $26.
2025-11-24 22:21
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
2025-11-11 10:49
